Senju Pharma has launched a new drug for dry eye disease (DED) in Japan, Avarept, which is the first drug in the TRPV1 ...
The FDA has approved orforglipron, under the Foundayo trade name, in just 50 days, thanks to a fast track review under the ...
For many life sciences start-ups, bringing on a GC early can be a strategic advantage. An experienced GC can help shape the ...
Avalyn's inhaled therapies use a nebuliser technology developed by PARI. Boston-based biotech Avalyn Pharma is the latest to hop on the IPO train, filing to list on the Nasdaq and raise funds for late ...
Healthcare in the UK is at an inflection point. To ensure the NHS remains fit for the future, the Government launched its 10-Year Health Plan for England last year, setting out strong ambitions around ...
In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh spoke with Lance Baldo, CEO of Beacon Therapeutics, a ...
Roche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs), developed by longtime ...
The only gene-editing therapy approved for beta-thalassaemia at present is Vertex Pharma's CRISPR-based Casgevy ...
AZ has yet to file for approval of Imfinzi in the frontline setting for earlier-stage HCC, despite its well-established role ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results